Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Waxman

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Trustee : the Journal for Hospital Governing Boards|February 1, 1993
Views from Capitol Hill--11 congressional leaders paint varying reform scenarios. Interview by Marybeth BurkeG Mitchell, J Rockefeller, N Johnson, et al.
Hospitals & Health Networks|January 20, 1994
The voices of reform. The final stretch. Interview by Renee BlankenauG Mitchell, J McDermott, J Chafee, et al.
Hospitals|January 20, 1993
Thirteen views from the Hill. Congressional leaders paint varying reform scenarios. Interview by Marybeth BurkeG Mitchell, J Rockefeller, B Gradison, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
EVA treatment for recurrent or unresponsive Hodgkin's diseaseM A Richards, J H Waxman, T Man, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The treatment of postmenopausal women with advanced breast cancer with buserelinJ H Waxman, S J Harland, R C Coombes, et al.
Acta Endocrinologica|March 1, 1989
Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancerJ H Waxman, J Sandow, P Abel, et al.
Seminars in Oncology|June 1, 1985
High-dose cytosine arabinoside in the initial treatment of acute leukemiaM J Barnett, J H Waxman, M A Richards, et al.
British Medical Journal (Clinical Research Ed.)|December 4, 1982
Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapyJ H Waxman, Y A Terry, P F Wrigley, et al.
British Medical Journal (Clinical Research Ed.)|April 23, 1983
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancerJ H Waxman, J A Wass, W F Hendry, et al.
Seminars in Oncology|June 1, 1985
The use of high-dose cytosine arabinoside for non-Hodgkin's lymphomaM A Richards, M J Barnett, J H Waxman, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Trustee : the Journal for Hospital Governing Boards|February 1, 1993
Views from Capitol Hill--11 congressional leaders paint varying reform scenarios. Interview by Marybeth BurkeG Mitchell, J Rockefeller, N Johnson, et al.
Hospitals & Health Networks|January 20, 1994
The voices of reform. The final stretch. Interview by Renee BlankenauG Mitchell, J McDermott, J Chafee, et al.
Hospitals|January 20, 1993
Thirteen views from the Hill. Congressional leaders paint varying reform scenarios. Interview by Marybeth BurkeG Mitchell, J Rockefeller, B Gradison, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
EVA treatment for recurrent or unresponsive Hodgkin's diseaseM A Richards, J H Waxman, T Man, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The treatment of postmenopausal women with advanced breast cancer with buserelinJ H Waxman, S J Harland, R C Coombes, et al.
Acta Endocrinologica|March 1, 1989
Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancerJ H Waxman, J Sandow, P Abel, et al.
Seminars in Oncology|June 1, 1985
High-dose cytosine arabinoside in the initial treatment of acute leukemiaM J Barnett, J H Waxman, M A Richards, et al.
British Medical Journal (Clinical Research Ed.)|December 4, 1982
Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapyJ H Waxman, Y A Terry, P F Wrigley, et al.
British Medical Journal (Clinical Research Ed.)|April 23, 1983
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancerJ H Waxman, J A Wass, W F Hendry, et al.
Seminars in Oncology|June 1, 1985
The use of high-dose cytosine arabinoside for non-Hodgkin's lymphomaM A Richards, M J Barnett, J H Waxman, et al.
Pageof 6